Intraductal carcinoma of the prostate: A comprehensive and updated review

International Journal of Urology

Volumn 22, Issue 2, 2015, Pages 140-145

  Tsuzuki, Toyonori ^a  

^a NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

Author keywords

Diagnostic criteria; Intraductal carcinoma of the prostate; Prognosis

Indexed keywords

CANCER DIAGNOSIS; CANCER MORPHOLOGY; CARCINOMA IN SITU; DIAGNOSTIC CRITERIA; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; FOLLOW UP; GLEASON SCORE; HIGH GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA; HISTORY; HUMAN; MALE; MEDICAL HISTORY; MORPHOLOGICAL TRAIT; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE; PROSTATE ADENOCARCINOMA; PROSTATE CARCINOMA; PROSTATE DUCTAL ADENOCARCINOMA; PROSTATE INTRADUCTAL CARCINOMA; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; TRANSITIONAL CELL CARCINOMA; TUMOR INVASION; INTRADUCTAL CARCINOMA; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR VOLUME;

BIOPSY, NEEDLE; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; TUMOR BURDEN;

EID: 84922631326     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12657     Document Type: Review

References (38)

1. Rhamy RK, Buchanan RD, Spalding MJ. Intraductal carcinoma of the prostate gland. J. Urol. 1973; 109: 457-460.
2. Catalona WJ, Kadmon D, Martin SA. Surgical considerations in treatment of intraductal carcinoma of the prostate. J. Urol. 1978; 120: 259-261.
3. Kovi J, Jackson MA, Heshmat MY. Ductal spread in prostatic carcinoma. Cancer 1985; 56: 1566-1573.
4. McNeal JE, Reese JH, Redwine EA, Freiha FS, Stamey TA. Cribriform adenocarcinoma of the prostate. Cancer 1986; 58: 1714-1719.
5. Bostwick DG, Brawer MK. Prostatic intra-epithelial neoplasia and early invasion in prostate cancer. Cancer 1987; 59: 788-794.
6. McNeal JE, Yemoto CE. Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. Am. J. Surg. Pathol. 1996; 20: 802-814.
7. Guo CC, Epstein JI. Intraductal carcinoma of the prostate on needle biopsy: histologic features and clinical significance. Mod. Pathol. 2006; 19: 1528-1535.
8. Robinson BD, Epstein JI. Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings. J. Urol. 2010; 184: 1328-1333.
9. Rubin MA, de La Taille A, Bagiella E, Olsson CA, O'Toole KM. Cribriform carcinoma of the prostate and cribriform prostatic intraepithelial neoplasia: incidence and clinical implications. Am. J. Surg. Pathol. 1998; 22: 840-848.
10. Cohen RJ, McNeal JE, Baillie T. Patterns of differentiation and proliferation in intraductal carcinoma of the prostate: significance for cancer progression. Prostate 2000; 43: 11-19.
11. Cohen RJ, Wheeler TM, Bonkhoff H, Rubin MA. A proposal on the identification, histologic reporting, and implications of intraductal prostatic carcinoma. Arch. Pathol. Lab. Med. 2007; 131: 1103-1109.
12. Watts K, Li J, Magi-Galluzzi C, Zhou M. Incidence and clinicopathological characteristics of intraductal carcinoma detected in prostate biopsies: a prospective cohort study. Histopathology 2013; 63: 574-579.
13. Shah RB, Magi-Galluzzi C, Han B, Zhou M. Atypical cribriform lesions of the prostate: relationship to prostatic carcinoma and implication for diagnosis in prostate biopsies. Am. J. Surg. Pathol. 2010; 34: 470-477.
14. Kimura K, Tsuzuki T, Kato M etal. Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens. Prostate 2014; 74: 680-687.
15. Ayala AG, Srigley JR, Ro JY, Abdul-Karim FW, Johnson DE. Clear cell cribriform hyperplasia of prostate. Report of 10 cases. Am. J. Surg. Pathol. 1986; 10: 665-671.
16. Rioux-Leclercq NC, Epstein JI. Unusual morphologic patterns of basal cell hyperplasia of the prostate. Am. J. Surg. Pathol. 2002; 26: 237-243.
17. Lotan TL, Gumuskaya B, Rahimi H etal. Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia. Mod. Pathol. 2013; 26: 587-603.
18. Han B, Suleman K, Wang L etal. ETS gene aberrations in atypical cribriform lesions of the prostate: implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia. Am. J. Surg. Pathol. 2010; 34: 478-485.
19. Bonkhoff H, Wheeler TM, van der Kwast TH, Magi-Galluzzi C, Montironi R, Cohen RJ. Intraductal carcinoma of the prostate: precursor or aggressive phenotype of prostate cancer? Prostate 2013; 73: 442-448.
20. Kryvenko ON, Gupta NS, Virani N etal. Gleason score 7 adenocarcinoma of the prostate with lymph node metastases: analysis of 184 radical prostatectomy specimens. Arch. Pathol. Lab. Med. 2013; 137: 610-617.
21. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am. J. Surg. Pathol. 2005; 29: 1228-1242.
22. Pickup M, Van der Kwast TH. My approach to intraductal lesions of the prostate gland. J. Clin. Pathol. 2007; 60: 856-865.
23. Qian J, Jenkins RB, Bostwick DG. Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization. Mod. Pathol. 1997; 10: 1113-1119.
24. Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res. 1997; 57: 524-531.
25. Dawkins HJ, Sellner LN, Turbett GR etal. Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression. Prostate 2000; 44: 265-270.
26. Bettendorf O, Schmidt H, Staebler A etal. Chromosomal imbalances, loss of heterozygosity, and immunohistochemical expression of TP53, RB1, and PTEN in intraductal cancer, intraepithelial neoplasia, and invasive adenocarcinoma of the prostate. Genes Chromosomes Cancer 2008; 47: 565-572.
27. Tomlins SA, Rhodes DR, Perner S etal. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-648.
28. Demichelis F, Fall K, Perner S etal. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007; 26: 4596-4599.
29. Wilcox G, Soh S, Chakraborty S, Scardino PT, Wheeler TM. Patterns of high-grade prostatic intraepithelial neoplasia associated with clinically aggressive prostate cancer. Hum. Pathol. 1998; 29: 1119-1123.
30. Miyai K, Divatia MK, Shen SS, Miles BJ, Ayala AG, Ro JY. Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions. Int. J. Clin. Exp. Pathol. 2014; 7: 2518-2526.
31. Iwata T, Schultz D, Hicks J etal. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS ONE 2010; 5: e9427.
32. O'Brien C, True LD, Higano CS, Rademacher BL, Garzotto M, Beer TM. Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer. Am. J. Clin. Pathol. 2010; 133: 654-661.
33. O'Brien BA, Cohen RJ, Wheeler TM, Moorin RE. A post-radical-prostatectomy nomogram incorporating new pathological variables and interaction terms for improved prognosis. BJU Int. 2011; 107: 389-395.
34. Miyai K, Divatia MK, Shen SS, Miles BJ, Ayala AG, Ro JY. Clinicopathological analysis of intraductal proliferative lesions of prostate: intraductal carcinoma of prostate, high-grade prostatic intraepithelial neoplasia, and atypical cribriform lesion. Hum. Pathol. 2014; 45: 1572-1581.
35. Efstathiou E, Abrahams NA, Tibbs RF etal. Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification. Eur. Urol. 2010; 57: 1030-1038.
36. Van der Kwast T, Al Daoud N, Collette L etal. Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy. Eur. J. Cancer 2012; 48: 1318-1325.
37. Gleason DF. Histologic grading of prostate cancer: a perspective. Hum. Pathol. 1992; 23: 273-279.
38. Epstein JI. An update of the Gleason grading system. J. Urol. 2010; 183: 433-440.